• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

西拉普利的化学设计。

Chemical design of cilazapril.

作者信息

Attwood M R

机构信息

Roche Products Ltd, Welwyn Garden City, Hertfordshire.

出版信息

Br J Clin Pharmacol. 1989;27 Suppl 2(Suppl 2):133S-137S. doi: 10.1111/j.1365-2125.1989.tb03474.x.

DOI:10.1111/j.1365-2125.1989.tb03474.x
PMID:2548550
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1379740/
Abstract
  1. The three dimensional requirements for inhibition of ACE (angiotensin converting enzyme) were investigated in order to facilitate design of a more potent and selective antihypertensive agent. 2. All compounds designed possessed a bicyclic unit incorporating carboxylate and amidic carbonyl groups together with a thiol-bearing side chain. 3. NMR spectroscopy of the bicyclic units and molecular mechanics calculations enabled the possible positions of the thiol group to be studied. 4. Determination of the positions of the thiol group conferring best inhibition in the active site of ACE permitted the probable location of the active site zinc ion to be identified. The intention was to replace the thiol side chain with a homophenylalanine unit to bind to the zinc ion and also to occupy the S1 site which fits the Phe8 side chain of angiotensin I. 5. Examination of a torsional angle psi in a compound possessing poor inhibitory potency indicated correspondence to a high energy conformation of alanylproline. The bicyclic unit was modified to incorporate a seven-instead of a six-membered ring to bring psi into the range of an accessible conformation of alanylproline. The corresponding IC50 resulting indicated that psi was closer to that of the active conformations of enalaprilat and captopril. 6. Removal of one carbonyl improved the ACE inhibitory potency further. 7. The postulated active conformation of cilazaprilat is presented.
摘要
  1. 为了便于设计出更有效且更具选择性的抗高血压药物,对抑制血管紧张素转换酶(ACE)的三维要求进行了研究。2. 所设计的所有化合物都具有一个双环单元,该单元包含羧酸盐和酰胺羰基,以及一个带有硫醇的侧链。3. 双环单元的核磁共振光谱和分子力学计算使得能够研究硫醇基团的可能位置。4. 确定在ACE活性位点中赋予最佳抑制作用的硫醇基团位置,有助于识别活性位点锌离子的可能位置。目的是用高苯丙氨酸单元取代硫醇侧链,以结合锌离子,并占据适合血管紧张素I的苯丙氨酸8侧链的S1位点。5. 对一种抑制效力较差的化合物中的扭转角ψ进行检查,发现其与丙氨酰脯氨酸的高能构象相对应。对双环单元进行修饰,使其包含一个七元环而非六元环,以使ψ处于丙氨酰脯氨酸可及构象的范围内。由此得到的相应半数抑制浓度(IC50)表明,ψ更接近依那普利拉和卡托普利活性构象的扭转角。6. 去除一个羰基进一步提高了对ACE的抑制效力。7. 给出了西拉普利拉假定的活性构象。

相似文献

1
Chemical design of cilazapril.西拉普利的化学设计。
Br J Clin Pharmacol. 1989;27 Suppl 2(Suppl 2):133S-137S. doi: 10.1111/j.1365-2125.1989.tb03474.x.
2
Conformationally restricted inhibitors of angiotensin converting enzyme: synthesis and computations.血管紧张素转换酶的构象受限抑制剂:合成与计算
J Med Chem. 1986 Feb;29(2):251-60. doi: 10.1021/jm00152a014.
3
A review of the preclinical cardiovascular pharmacology of cilazapril, a new angiotensin converting enzyme inhibitor.新型血管紧张素转换酶抑制剂西拉普利的临床前心血管药理学综述。
Br J Clin Pharmacol. 1989;27 Suppl 2(Suppl 2):139S-150S. doi: 10.1111/j.1365-2125.1989.tb03475.x.
4
New potent inhibitors of angiotensin converting enzyme.
FEBS Lett. 1984 Jan 9;165(2):201-6. doi: 10.1016/0014-5793(84)80169-6.
5
The assessment of ACE activity in man following angiotensin I challenges: a comparison of cilazapril, captopril and enalapril.人在接受血管紧张素I激发后血管紧张素转换酶(ACE)活性的评估:西拉普利、卡托普利和依那普利的比较
Br J Clin Pharmacol. 1989;27 Suppl 2(Suppl 2):217S-223S. doi: 10.1111/j.1365-2125.1989.tb03485.x.
6
Enalaprilat, but not cilazaprilat, increases inflammatory skin reactions in guinea-pigs.
Drugs. 1991;41 Suppl 1:48-53. doi: 10.2165/00003495-199100411-00009.
7
The pharmacokinetics and dose proportionality of cilazapril.西拉普利的药代动力学及剂量比例关系。
Br J Clin Pharmacol. 1989;27 Suppl 2(Suppl 2):199S-204S. doi: 10.1111/j.1365-2125.1989.tb03482.x.
8
The pharmacokinetics and bioavailability of cilazapril in normal man.西拉普利在正常人体内的药代动力学和生物利用度。
Br J Clin Pharmacol. 1989;27 Suppl 2(Suppl 2):181S-188S. doi: 10.1111/j.1365-2125.1989.tb03480.x.
9
Effects of ACE inhibition with cilazapril on splanchnic and systemic haemodynamics in man.西拉普利抑制ACE对人体内脏和全身血流动力学的影响。
Br J Clin Pharmacol. 1989;27 Suppl 2(Suppl 2):225S-234S. doi: 10.1111/j.1365-2125.1989.tb03486.x.
10
The pharmacokinetics and angiotensin converting enzyme inhibition dynamics of cilazapril in essential hypertension.西拉普利在原发性高血压中的药代动力学及血管紧张素转换酶抑制动力学
Br J Clin Pharmacol. 1989;27 Suppl 2(Suppl 2):263S-266S. doi: 10.1111/j.1365-2125.1989.tb03490.x.

引用本文的文献

1
Bioproduction of L-piperazic acid in gram scale using Aureobasidium melanogenum.利用嗜热枝孢霉在克级规模生产 L-哌嗪酸。
Microb Biotechnol. 2021 Jul;14(4):1722-1729. doi: 10.1111/1751-7915.13838. Epub 2021 Jun 3.
2
Clinical pharmacokinetics of the newer ACE inhibitors. A review.新型血管紧张素转换酶抑制剂的临床药代动力学。综述。
Clin Pharmacokinet. 1990 Sep;19(3):177-96. doi: 10.2165/00003088-199019030-00003.

本文引用的文献

1
The existence of two forms of hypertensin.高血压素两种形式的存在。
J Exp Med. 1954 Mar;99(3):275-82. doi: 10.1084/jem.99.3.275.
2
Structure of a mercaptan-thermolysin complex illustrates mode of inhibition of zinc proteases by substrate-analogue mercaptans.硫醇-嗜热菌蛋白酶复合物的结构阐明了底物类似物硫醇对锌蛋白酶的抑制模式。
Biochemistry. 1982 Jul 6;21(14):3390-4. doi: 10.1021/bi00257a022.
3
Binding of N-carboxymethyl dipeptide inhibitors to thermolysin determined by X-ray crystallography: a novel class of transition-state analogues for zinc peptidases.通过X射线晶体学确定N-羧甲基二肽抑制剂与嗜热菌蛋白酶的结合:一类新型的锌肽酶过渡态类似物
Biochemistry. 1984 Nov 20;23(24):5724-9. doi: 10.1021/bi00319a010.
4
New potent inhibitors of angiotensin converting enzyme.
FEBS Lett. 1984 Jan 9;165(2):201-6. doi: 10.1016/0014-5793(84)80169-6.
5
A new class of angiotensin-converting enzyme inhibitors.一类新型的血管紧张素转换酶抑制剂。
Nature. 1980 Nov 20;288(5788):280-3. doi: 10.1038/288280a0.
6
Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents.血管紧张素转换酶特异性抑制剂的设计:新型口服活性抗高血压药物
Science. 1977 Apr 22;196(4288):441-4. doi: 10.1126/science.191908.